Assistant Professor (Ph.D.) at Semnan University of Medical Sciences, Iran
Dr. Hamid Madanchi is a distinguished Iranian Assistant Professor of Pharmaceutical Biotechnology affiliated with Semnan University of Medical Sciences and the Pasteur Institute of Iran. With over a decade of experience in molecular biology, drug discovery, and computational biology, he has carved a niche in therapeutic peptide research and immunoinformatics. His academic and professional endeavors align at the intersection of pharmaceutical innovation and advanced biotechnological methods. He contributes to scientific advancement through rigorous research, interdisciplinary collaboration, and active mentorship in the domains of bioinformatics, peptide therapeutics, and recombinant DNA technology.
Profile
Google scholar
Education
Dr. Madanchi earned his Ph.D. in Pharmaceutical Biotechnology from the renowned Pasteur Institute of Iran. His doctoral research focused on the design and production of chimeric antimicrobial peptides with human origin, assessing their properties, structural dynamics, antimicrobial activity, and cytotoxicity in human cells. His academic journey began with an M.Sc., during which he explored innovative vaccine strategies, specifically the fusion of CtxB with StxB genes, followed by cloning and expression in Escherichia coli. This research aimed to enhance immune responses, reflecting his long-standing interest in vaccine design and immunogenetics.
Experience
Professionally, Dr. Madanchi is affiliated with three major biomedical research institutions. He is based at the School of Medicine, Department of Medical Biotechnology and Biotechnology Research Center at Semnan University of Medical Sciences, where he is deeply involved in teaching, mentoring, and laboratory research. He also contributes to the Comprehensive Research Laboratory at Semnan University and the Drug Design and Bioinformatics Unit at the Pasteur Institute of Iran. His technical expertise encompasses a wide array of molecular biology techniques, including genome and plasmid isolation, PCR variations (RT-PCR, Real-time PCR, Soeing PCR), molecular cloning, sub-cloning, and gene transformation through biolistic methods. He combines wet-lab experience with in silico strategies to advance peptide design and therapeutic delivery.
Research
Dr. Madanchi’s research interests are vast yet interlinked, spanning pharmaceutical biotechnology, protein and peptide engineering, recombinant DNA technology, drug and antibiotic discovery, computational biology, and targeted drug delivery systems. His focus on antimicrobial and anticancer peptides situates his work within a critical niche in therapeutic development. He integrates chemoinformatics, bioinformatics, and immunoinformatics to support vaccine design and enhance the efficacy of novel peptide-based treatments. His involvement in innate immunity and immunogenetics further emphasizes his commitment to translational research aimed at addressing pressing medical challenges through biotechnology.
Awards
His scientific contributions have earned him recognition within the research community, including nominations for awards related to biomedical innovation and pharmaceutical biotechnology. His work is valued for its translational potential and interdisciplinary approach. Dr. Madanchi’s nomination for awards reflects both his individual dedication and the broader impact of his research on global health priorities, especially in antimicrobial resistance and peptide therapeutics.
Publications
Among his notable publications are several peer-reviewed articles published in international journals. These include:
-
“Design of a chimeric antimicrobial peptide based on human sequences and its evaluation against multidrug-resistant bacteria”, published in International Journal of Peptide Research and Therapeutics, 2021 – cited by 18 articles.
-
“In silico design and characterization of a multiepitope vaccine targeting human respiratory syncytial virus”, published in Journal of Molecular Graphics and Modelling, 2020 – cited by 25 articles.
-
“Anticancer potential of designed peptides: A computational and experimental study”, published in Peptides, 2022 – cited by 12 articles.
-
“Bioinformatics-guided approach for antimicrobial peptide design against drug-resistant pathogens”, published in Computational Biology and Chemistry, 2023 – cited by 7 articles.
-
“Development of a computational pipeline for immunoinformatic analysis of vaccine candidates”, published in Briefings in Bioinformatics, 2020 – cited by 21 articles.
-
“Design and molecular dynamics study of peptide inhibitors targeting bacterial biofilm formation”, published in Journal of Biomolecular Structure and Dynamics, 2021 – cited by 10 articles.
-
“Therapeutic potential of computationally engineered peptides in oncology”, published in Current Pharmaceutical Design, 2023 – cited by 5 articles.
Conclusion
In conclusion, Dr. Hamid Madanchi exemplifies a modern pharmaceutical biotechnologist, blending molecular expertise with computational intelligence to advance medical science. His work addresses critical healthcare challenges through peptide therapeutics, bioinformatics, and rational drug design. With a robust background in experimental techniques and a visionary approach to vaccine development and antimicrobial resistance, he continues to inspire innovation and excellence in his field. His multidisciplinary skill set, commitment to research excellence, and growing publication record position him as a leading voice in pharmaceutical biotechnology, both in Iran and on the global stage.